Regional One Health and UTHSC to conduct clinical trials of Regeneron's COVID treatment
September 24, 2020 at 18:25 PM EDT
The Regeneron drug candidate consists of a two-antibody cocktail that binds to SARS-CoV2’s spike protein, which potentially neutralizes the virus’ ability to attach to human cells.
